Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) Consolidated Net Income (2016 - 2025)

Historic Consolidated Net Income for Ani Pharmaceuticals (ANIP) over the last 15 years, with Q3 2025 value amounting to $26.6 million.

  • Ani Pharmaceuticals' Consolidated Net Income rose 21007.2% to $26.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.5 million, marking a year-over-year increase of 67156.96%. This contributed to the annual value of -$18.5 million for FY2024, which is 19863.15% down from last year.
  • Ani Pharmaceuticals' Consolidated Net Income amounted to $26.6 million in Q3 2025, which was up 21007.2% from $8.5 million recorded in Q2 2025.
  • Ani Pharmaceuticals' Consolidated Net Income's 5-year high stood at $26.6 million during Q3 2025, with a 5-year trough of -$24.2 million in Q3 2024.
  • Its 5-year average for Consolidated Net Income is -$2.1 million, with a median of -$2.3 million in 2024.
  • Its Consolidated Net Income has fluctuated over the past 5 years, first plummeted by 1837272.73% in 2022, then skyrocketed by 113521.03% in 2024.
  • Quarter analysis of 5 years shows Ani Pharmaceuticals' Consolidated Net Income stood at -$24.1 million in 2021, then soared by 82.35% to -$4.3 million in 2022, then soared by 127.12% to $1.2 million in 2023, then plummeted by 989.7% to -$10.3 million in 2024, then soared by 358.86% to $26.6 million in 2025.
  • Its last three reported values are $26.6 million in Q3 2025, $8.5 million for Q2 2025, and $15.7 million during Q1 2025.